PT Kimia Farma Tbk (ISX:KAEF) Piotroski F-Score: 6 (As of Jun. 28, 2026) — 20% Above Median


ISX:KAEF PT Kimia Farma Tbk ISX:KAEF
56 GF Score
Price Rp456.00
GF Value Rp581.98
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is PT Kimia Farma Tbk Piotroski F-Score?

PT Kimia Farma Tbk ISX:KAEF -2.15% 56 Piotroski F-Score is 6 as of Jun. 28, 2026, which is 20% above its 10-year median of 5.00. GuruFocus rates ISX:KAEF with a GF Score™ of 56/100 and a GF Value™ of Rp581.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 112 Medical Distribution companies, PT Kimia Farma Tbk ranks better than 76.79% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PT Kimia Farma Tbk has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for PT Kimia Farma Tbk's Piotroski F-Score or its related term are showing as below:

ISX:KAEF' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 6

During the past 13 years, the highest Piotroski F-Score of PT Kimia Farma Tbk was 7. The lowest was 2. And the median was 5.

PT Kimia Farma Tbk  (ISX:KAEF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PT Kimia Farma Tbk Piotroski F-Score Related Terms


PT Kimia Farma Tbk Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for PT Kimia Farma Tbk's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kimia Farma Tbk Piotroski F-Score Chart

PT Kimia Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 3.00 5.00 6.00

PT Kimia Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 6.00 6.00

ISX:KAEF vs MCK, COR, CAH: Piotroski F-Score Comparison

For the Medical Distribution subindustry, PT Kimia Farma Tbk's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Kimia Farma Tbk Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Tbk's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PT Kimia Farma Tbk's Piotroski F-Score falls into.


ISX:KAEF
56GF Score
PT Kimia Farma Tbk ISX:KAEF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 7162.125 + -84716.853 + -155227.354 + 74449.544 = Rp-158,333 Mil.
Cash Flow from Operations was 54662.802 + 190619.856 + 118549.345 + 87100.568 = Rp450,933 Mil.
Revenue was 2201140.777 + 2638862.719 + 2215116.743 + 2030649.486 = Rp9,085,770 Mil.
Gross Profit was 818623.117 + 883784.799 + 618330.791 + 824816.869 = Rp3,145,556 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(15026459.88 + 14973271.31 + 14910941.488 + 14183178.39 + 14358871.134) / 5 = Rp14690544.4404 Mil.
Total Assets at the begining of this year (Mar25) was Rp15,026,460 Mil.
Long-Term Debt & Capital Lease Obligation was Rp4,519,153 Mil.
Total Current Assets was Rp4,316,463 Mil.
Total Current Liabilities was Rp6,091,613 Mil.
Net Income was -124048.017 + -195052.487 + -420438.304 + -102177.254 = Rp-841,716 Mil.

Revenue was 2677916.631 + 2650568.513 + 2074694.366 + 2168207.817 = Rp9,571,387 Mil.
Gross Profit was 758846.042 + 773933.181 + 592857.115 + 742671.671 = Rp2,868,308 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(17343272.196 + 17067208.218 + 16802347.355 + 14928543.991 + 15026459.88) / 5 = Rp16233566.328 Mil.
Total Assets at the begining of last year (Mar24) was Rp17,343,272 Mil.
Long-Term Debt & Capital Lease Obligation was Rp3,996,331 Mil.
Total Current Assets was Rp4,059,560 Mil.
Total Current Liabilities was Rp6,678,251 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PT Kimia Farma Tbk's current Net Income (TTM) was -158,333. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PT Kimia Farma Tbk's current Cash Flow from Operations (TTM) was 450,933. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-158332.538/15026459.88
=-0.01053692

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-841716.062/17343272.196
=-0.04853271

PT Kimia Farma Tbk's return on assets of this year was -0.01053692. PT Kimia Farma Tbk's return on assets of last year was -0.04853271. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PT Kimia Farma Tbk's current Net Income (TTM) was -158,333. PT Kimia Farma Tbk's current Cash Flow from Operations (TTM) was 450,933. ==> 450,933 > -158,333 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=4519152.569/14690544.4404
=0.30762322

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=3996330.683/16233566.328
=0.246177

PT Kimia Farma Tbk's gearing of this year was 0.30762322. PT Kimia Farma Tbk's gearing of last year was 0.246177. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=4316462.955/6091613.427
=0.70859108

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=4059560.197/6678251.492
=0.60787771

PT Kimia Farma Tbk's current ratio of this year was 0.70859108. PT Kimia Farma Tbk's current ratio of last year was 0.60787771. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PT Kimia Farma Tbk's number of shares in issue this year was 5566.588. PT Kimia Farma Tbk's number of shares in issue last year was 5566.585. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3145555.576/9085769.725
=0.34620683

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2868308.009/9571387.327
=0.29967526

PT Kimia Farma Tbk's gross margin of this year was 0.34620683. PT Kimia Farma Tbk's gross margin of last year was 0.29967526. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=9085769.725/15026459.88
=0.60465138

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=9571387.327/17343272.196
=0.55187898

PT Kimia Farma Tbk's asset turnover of this year was 0.60465138. PT Kimia Farma Tbk's asset turnover of last year was 0.55187898. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+1+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PT Kimia Farma Tbk has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
PT Kimia Farma Tbk (ISX:KAEF) has a Piotroski F-Score of 6 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Kimia Farma Tbk and its competitors. This is 20% above median its historical median of 5.00. Over the past decade, PT Kimia Farma Tbk's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, PT Kimia Farma Tbk ranks #26 out of 112 companies in the Medical Distribution industry, placing it in the top 23.2%.
Is PT Kimia Farma Tbk's Piotroski F-Score too high?
PT Kimia Farma Tbk's current Piotroski F-Score of 6 is 20% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Distribution industry median Piotroski F-Score is 5.00. PT Kimia Farma Tbk's value of 6 is 20% above this industry median. Based on the distribution chart, PT Kimia Farma Tbk ranks #26 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kimia Farma Tbk has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Tbk ranks #26 out of 112 companies for Piotroski F-Score. This places PT Kimia Farma Tbk in the top 23% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. PT Kimia Farma Tbk's value of 6 is 20% above this benchmark. Historically, PT Kimia Farma Tbk's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, PT Kimia Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Tbk's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Kimia Farma Tbk and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Tbk's current Piotroski F-Score is 6, which is 20% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.98, compared to a current price of Rp456.00 — trading 21.6% below its estimated fair value. The current Piotroski F-Score is 6, which is 20% above median its 10-year median of 5.00 and 20% above the Medical Distribution industry median of 5.00. PT Kimia Farma Tbk's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current Piotroski F-Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued. The current stock price of Rp456.00 is trading 21.6% below its estimated GF Value™ of Rp581.98. GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.

Key valuation signals for ISX:KAEF:

  • Piotroski F-Score: 6 (20% above median its 10-year median of 5.00)
  • GF Value™: Rp581.98 vs. price of Rp456.00 (21.6% below fair value)
  • GF Score™: 56/100 with 4 warning signs
  • Industry Position: 20% above the Medical Distribution median (#26 of 112)

No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Kimia Farma Tbk Business Description

Address Jalan Veteran No. 9 Gambir, Jakarta Pusat, Jakarta, IDN, 10110
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
56GF Score

Get the complete analysis for ISX:KAEF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp456.00
Price
Rp581.98
GF Value